Skip to main content
. Author manuscript; available in PMC: 2013 Jan 12.
Published in final edited form as: Expert Opin Ther Targets. 2012 Jan 12;16(1):15–31. doi: 10.1517/14728222.2011.648617

Figure 3. Schematic representation of EGFR inhibition in multidimensional approaches.

Figure 3

(1) Therapeutic invention site for EGFR specific monoclonal antibodies (Cetuximab and Panitumumab), (2) Potential target for small molecule tyrosine kinase inhibitors (Gifitinib, Erlotinib, Lapatinib and Canertinib), (3) Synergistic role of chemopreventive agents (Genistein, Curcumin and Caspacin).